DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California. Show more

6340 Sequence Drive, San Diego, CA, 92121, United States

Medical Devices
Healthcare
Start AI Chat

Market Cap

28.57B

52 Wk Range

$54.11 - $91.87

Previous Close

$73.08

Open

$73.07

Volume

4,729,857

Day Range

$72.86 - $74.49

Enterprise Value

24.79B

Cash

1.999B

Avg Qtr Burn

N/A

Insider Ownership

1.08%

Institutional Own.

-

Qtr Updated

12/31/25


Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date